SYN-AKE vs Palmitoyl Hexapeptide-12
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Dipeptide diaminobutyroyl benzylamide diacetate, SYN-AKE
SYN-AKE is DSM's trade name for dipeptide diaminobutyroyl benzylamide diacetate, the 'snake venom' peptide in a lot of anti-wrinkle creams. The marketing says it mimics Waglerin-1, a toxin from the temple viper. To be clear: there is no venom in it. It is a tiny synthetic molecule, and the evidence that it relaxes wrinkles comes almost entirely from the manufacturer.
Also: Biopeptide EL, Pal-VGVAPG
Palmitoyl hexapeptide-12 is the six-amino-acid sequence VGVAPG, a repeating piece of elastin, with a fatty acid tail attached so it can get into skin. It is sold under the trade name Biopeptide EL and pitched for firmness and elasticity, the bounce-back that fades with age. It is a cosmetic ingredient, not an FDA-approved drug, and nobody has published an independent clinical trial showing it visibly changes skin.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
Detailed Comparison
| Attribute | SYN-AKE | Palmitoyl Hexapeptide-12 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | DSM describes SYN-AKE as a reversible blocker of the muscle-type nicotinic acetylcholine receptor, the receptor on muscle that acetylcholine opens to make it contract. Block it, the theory goes, and facial muscles relax a little. That is the real mechanism of Waglerin-1, a 22-amino-acid viper toxin that independent research shows selectively blocks the adult form of this receptor. SYN-AKE itself is a much smaller molecule (beta-alanine, proline and diaminobutyric acid with a benzylamide end, under 500 daltons), and the claim that it does the same thing comes from the manufacturer's own cell test, where innervated muscle cells contracted less. Even DSM's older material calls the binding 'probable'. As with Argireline, there is no independent proof that a cream gets enough of it to facial muscle to matter. | VGVAPG repeats many times in elastin, the protein that lets skin snap back. When elastin breaks down, fragments like this are released, and back in 1984 researchers showed VGVAPG attracts fibroblasts and monocytes in the lab, which is the basis for calling it a matrikine: a matrix fragment that tells repair cells to show up and get to work. The palmitoyl tail makes the peptide fat-friendly enough to cross the outer skin layer. A 2025 ex vivo study added a twist: on human skin samples the peptide reached the epidermis, used the skin's own calcium to form a gel, and helped dried-out, lipid-stripped skin hold water and stay less stiff. That reads more like a barrier and film effect than proof of new elastin being built. |
| Common Dosing | 1-4% of the SYN-AKE solution in a finished product Once or twice daily | About 4% of the ingredient solution in a finished product Once or twice daily |
| Administration | Topical (serums, creams) | Topical (serums, creams) |
| Typical Duration | 28 days in the manufacturer study; ongoing use to maintain any effect | Manufacturer study ran one month; ongoing use for any maintained effect |
| Best Time to Take | Morning and/or evening, on clean skin | Morning and/or evening skincare routine |
Possible Side Effects May vary by individual |
|
|
| Research Summary | DSM's brochure reports two pieces of data. In vitro, 0.5 mM of the peptide cut the contraction frequency of innervated muscle cells. In vivo, a 4% SYN-AKE cream was compared with placebo in 15 volunteers per group (aged 40-60), applied twice daily for 28 days, with reductions of roughly 15-21% in skin roughness and wrinkle measures and a headline of 'up to 52%' wrinkle reduction in the best responders. A US patent also describes a double-blind study in 59 women aged 40-55 reporting smaller pores and less shine after 28 days, but that is a patent filing, not a peer-reviewed paper. A 2020 review of cosmetic peptides states plainly that there are no scientific papers describing clinical studies of this peptide, so the efficacy story rests on company data. Bottom line: a well-tolerated cosmetic ingredient with a catchy story. The venom angle is marketing, and the 'up to 52%' number is a best case from a 15-person company study, not a typical result. | The best peer-reviewed work is a 2025 paper in ACS Applied Bio Materials (Ligorio and colleagues, with co-authors from Estee Lauder) that tracked the peptide in full-thickness human skin from a single donor. It showed penetration into the stratum corneum and epidermis, gel formation driven by calcium, reduced water loss and drying stress in delipidated skin (roughly comparable to 5 percent glycerol for drying stress), and stronger gels when mixed with collagen. Useful mechanistic data, but small samples and no living people. The appearance claims come from the manufacturer: a one-month, double-blind study in 10 women using 4 percent Biopeptide EL twice daily reported 33 percent better firmness and 20 percent better tone. That study is not in PubMed and is far too small to lean on. A separate 2023 trial of an elastin-like recombinant polypeptide built on the same VGVAPG repeat found improved elasticity after 28 days in 30 women, but that was a different molecule. Honest read: plausible biology, real skin penetration, no independent proof of visible results. |
Frequently Asked Questions: SYN-AKE vs Palmitoyl Hexapeptide-12
What is the difference between SYN-AKE and Palmitoyl Hexapeptide-12?
SYN-AKE is a skin & hair peptide that syn-ake is dsm's trade name for dipeptide diaminobutyroyl benzylamide diacetate, the 'snake venom' peptide in a lot of anti-wrinkle creams. the marketing says it mimics waglerin-1, a toxin from the temple viper. to be clear: there is no venom in it. it is a tiny synthetic molecule, and the evidence that it relaxes wrinkles comes almost entirely from the manufacturer. Palmitoyl Hexapeptide-12 is a skin & hair peptide that palmitoyl hexapeptide-12 is the six-amino-acid sequence vgvapg, a repeating piece of elastin, with a fatty acid tail attached so it can get into skin. it is sold under the trade name biopeptide el and pitched for firmness and elasticity, the bounce-back that fades with age. it is a cosmetic ingredient, not an fda-approved drug, and nobody has published an independent clinical trial showing it visibly changes skin. The main differences lie in their mechanisms of action and clinical applications.
Which is better, SYN-AKE or Palmitoyl Hexapeptide-12?
Neither is universally "better" - the choice depends on your specific goals. SYN-AKE is typically used for skin & hair purposes, while Palmitoyl Hexapeptide-12 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can SYN-AKE and Palmitoyl Hexapeptide-12 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using SYN-AKE and Palmitoyl Hexapeptide-12 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.